GLS and neoplasm: Recent research has focused on allosteric inhibitors of GLS1 in tumor glutamine metabolism; however, progress has been limited and clinical trials have been halted.[11, 12] Our studies demonstrated that both the novel macrocyclic GLS1 inhibitor LL202[13] developed by our group and the clinical drug CB839[14] did not elicit satisfactory anti‐tumor activity in vivo as monotherapies.